Role of microRNAs in the SV40 infectious cycle

microRNA 在 SV40 感染周期中的作用

基本信息

  • 批准号:
    8317622
  • 负责人:
  • 金额:
    $ 26.63万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2009
  • 资助国家:
    美国
  • 起止时间:
    2009-09-07 至 2014-08-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Many, if not all members of the Herpes and Polyoma virus families encode microRNAs (miRNAs). miRNAs function by binding to specific viral or cellular target mRNAs and inhibiting their expression. miRNA- mediated gene regulation has been implicated in important cellular processes such as tumorigenesis. Recent work from our laboratory has demonstrated that the miRNAs encoded by Simian Virus 40 (SVmiRNA) function to provide a growth advantage to infected cells undergoing an interferon response. Furthermore, expression of the gene encoding the SVmiRNAs prevents interferon-mediated apoptosis, implying an important role in evading a host antiviral defense. We have also uncovered several oncogenic cellular miRNAs that are induced upon infection with SV40. Although this work points to an important role for miRNAs in DNA tumor viral lifecycles, the mechanism of how SV40 induces expression of viral and cellular miRNAs and how this prevents apoptosis and contributes to transformation is not understood. The goal of this proposal is to determine the contribution of miRNAs to Polyomaviral infectivity and viral-induced transformation. To this end, three specific aims are proposed. These specific aims propose genetic and biochemical techniques to: (1) Identify the components of the interferon pathway that are responsible for Polyomaviral-induced apoptosis. (2) Determine the mechanism by which the Polyomaviral miRNA gene products prevent interferon-induced apoptosis. (3) Determine the role of virally-induced oncogenic cellular miRNAs in Polyomavirus replication and transformation. PUBLIC HEALTH RELEVANCE: Viral-mediated gene regulation is critical for pathogenicity. The goal of this project is to understand the role of microRNA-mediated gene regulation in the Simian Virus 40-induced transformation and the infectious cycle. Knowledge generated from this research may be applicable to other DNA tumor viruses and their associated human diseases.
描述(由申请人提供):疱疹和多瘤病毒家族中的许多成员(如果不是所有成员)编码microRNAs(MiRNAs)。MiRNAs通过与特定的病毒或细胞靶向的mRNAs结合并抑制其表达而发挥作用。MiRNA介导的基因调控参与了重要的细胞过程,如肿瘤的发生。我们实验室最近的工作表明,由猿猴病毒40(SVmiRNA)编码的miRNAs能够为经历干扰素应答的感染细胞提供生长优势。此外,编码SVmiRNAs的基因的表达阻止了干扰素介导的细胞凋亡,这意味着在逃避宿主抗病毒防御方面发挥了重要作用。我们还发现了几个致癌的细胞miRNAs,它们是在感染SV40时诱导的。虽然这项工作指出了miRNAs在DNA肿瘤病毒生命周期中的重要作用,但SV40如何诱导病毒和细胞miRNAs表达以及如何防止细胞凋亡和促进转化的机制尚不清楚。这项建议的目的是确定miRNAs对多瘤病毒感染性和病毒诱导转化的贡献。为此,提出了三个具体目标。这些特定的目的提出了遗传和生化技术来:(1)确定干扰素途径中负责多瘤病毒诱导的细胞凋亡的成分。(2)确定多瘤病毒miRNA基因产物阻止干扰素诱导的细胞凋亡的机制。(3)确定病毒诱导的致癌细胞miRNAs在多瘤病毒复制和转化中的作用。公共卫生相关性:病毒介导的基因调控对致病性至关重要。本项目的目的是了解microRNA介导的基因调控在猿猴病毒40诱导的转化和感染循环中的作用。这项研究产生的知识可能适用于其他DNA肿瘤病毒及其相关的人类疾病。

项目成果

期刊论文数量(19)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Virus-encoded microRNAs.
  • DOI:
    10.1016/j.virol.2011.01.002
  • 发表时间:
    2011-03-15
  • 期刊:
  • 影响因子:
    3.7
  • 作者:
    Grundhoff A;Sullivan CS
  • 通讯作者:
    Sullivan CS
Noncanonical microRNA (miRNA) biogenesis gives rise to retroviral mimics of lymphoproliferative and immunosuppressive host miRNAs.
  • DOI:
    10.1128/mbio.00074-14
  • 发表时间:
    2014-04-08
  • 期刊:
  • 影响因子:
    6.4
  • 作者:
    Kincaid RP;Chen Y;Cox JE;Rethwilm A;Sullivan CS
  • 通讯作者:
    Sullivan CS
Identification of tri-phosphatase activity in the biogenesis of retroviral microRNAs and RNAP III-generated shRNAs.
  • DOI:
    10.1093/nar/gku1247
  • 发表时间:
    2014-12-16
  • 期刊:
  • 影响因子:
    14.9
  • 作者:
    Burke JM;Bass CR;Kincaid RP;Sullivan CS
  • 通讯作者:
    Sullivan CS
RIDDLE: reflective diffusion and local extension reveal functional associations for unannotated gene sets via proximity in a gene network.
  • DOI:
    10.1186/gb-2012-13-12-r125
  • 发表时间:
    2012-12-26
  • 期刊:
  • 影响因子:
    12.3
  • 作者:
    Wang PI;Hwang S;Kincaid RP;Sullivan CS;Lee I;Marcotte EM
  • 通讯作者:
    Marcotte EM
Virus-encoded microRNAs: an overview and a look to the future.
  • DOI:
    10.1371/journal.ppat.1003018
  • 发表时间:
    2012-12
  • 期刊:
  • 影响因子:
    6.7
  • 作者:
    Kincaid RP;Sullivan CS
  • 通讯作者:
    Sullivan CS
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Christopher S. Sullivan其他文献

PARP14 is pro- and anti-viral host factor that promotes IFN production and affects the replication of multiple viruses
PARP14 是促病毒和抗病毒宿主因子,可促进 IFN 产生并影响多种病毒的复制
  • DOI:
    10.1101/2024.04.26.591186
  • 发表时间:
    2024
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Srivatsan Parthasarathy;Pradtahna Saenjamsai;Hongping Hao;Anna Ferkul;Jessica J. Pfannenstiel;Ellen L. Suder;Daniel S. Bejan;Yating Chen;N. Schwarting;Masanori Aikawa;Elke Muhlberger;Robin C. Orozco;Christopher S. Sullivan;Michael S. Cohen;D. Davido;A. Hume;Anthony R. Fehr
  • 通讯作者:
    Anthony R. Fehr

Christopher S. Sullivan的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Christopher S. Sullivan', 18)}}的其他基金

Non-coding RNA and ADP-ribosylation in Antiviral Defense
抗病毒防御中的非编码 RNA 和 ADP-核糖基化
  • 批准号:
    9982750
  • 财政年份:
    2017
  • 资助金额:
    $ 26.63万
  • 项目类别:
Non-coding RNA and ADP-ribosylation in Antiviral Defense
抗病毒防御中的非编码 RNA 和 ADP-核糖基化
  • 批准号:
    10204948
  • 财政年份:
    2017
  • 资助金额:
    $ 26.63万
  • 项目类别:
Role of microRNAs in the SV40 infectious cycle
microRNA 在 SV40 感染周期中的作用
  • 批准号:
    7927136
  • 财政年份:
    2009
  • 资助金额:
    $ 26.63万
  • 项目类别:
Role of microRNAs in the SV40 infectious cycle
microRNA 在 SV40 感染周期中的作用
  • 批准号:
    8133383
  • 财政年份:
    2009
  • 资助金额:
    $ 26.63万
  • 项目类别:
Role of microRNAs in the SV40 infectious cycle
microRNA 在 SV40 感染周期中的作用
  • 批准号:
    7731130
  • 财政年份:
    2009
  • 资助金额:
    $ 26.63万
  • 项目类别:

相似海外基金

Development of a new generation of antiviral agents that are effective against drug-resistant viruses and prevent serious illness and sequelae.
开发新一代抗病毒药物,可有效对抗耐药病毒并预防严重疾病和后遗症。
  • 批准号:
    23K18186
  • 财政年份:
    2023
  • 资助金额:
    $ 26.63万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
A versatile structure-based therapeutic platform for development of VHH-based antitoxin and antiviral agents
一个多功能的基于结构的治疗平台,用于开发基于 VHH 的抗毒素和抗病毒药物
  • 批准号:
    10560883
  • 财政年份:
    2023
  • 资助金额:
    $ 26.63万
  • 项目类别:
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
  • 批准号:
    10730692
  • 财政年份:
    2021
  • 资助金额:
    $ 26.63万
  • 项目类别:
Design and synthesis of nucleosides to develop antiviral agents and oligonucleotide therapeutics
设计和合成核苷以开发抗病毒药物和寡核苷酸疗法
  • 批准号:
    21K06459
  • 财政年份:
    2021
  • 资助金额:
    $ 26.63万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
  • 批准号:
    10189880
  • 财政年份:
    2021
  • 资助金额:
    $ 26.63万
  • 项目类别:
Computer-aided identification and synthesis of novel broad-spectrum antiviral agents
新型广谱抗病毒药物的计算机辅助鉴定和合成
  • 批准号:
    2404261
  • 财政年份:
    2020
  • 资助金额:
    $ 26.63万
  • 项目类别:
    Studentship
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10222540
  • 财政年份:
    2020
  • 资助金额:
    $ 26.63万
  • 项目类别:
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10669717
  • 财政年份:
    2020
  • 资助金额:
    $ 26.63万
  • 项目类别:
Association between sedentary lifestyle and liver cancer development in hepatitis C patients treated with direct-acting antiviral agents
接受直接抗病毒药物治疗的丙型肝炎患者久坐的生活方式与肝癌发展之间的关系
  • 批准号:
    20K10713
  • 财政年份:
    2020
  • 资助金额:
    $ 26.63万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10174522
  • 财政年份:
    2020
  • 资助金额:
    $ 26.63万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了